Last updated on November 2019

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors


Find a site near you

Start Over

Netherlands Cancer Institute

Amsterdam, Netherlands
0.39miles
  Connect »